| Literature DB >> 35282152 |
Tomoki Aoyama1,2, Koji Goto3, Ryosuke Ikeguchi2,3, Manabu Nankaku4, Katsuyuki Madoba5, Momoko Nagai-Tanima1, Akira Ito1, Ryosuke Kakinoki3, Takashi Nakamura3, Shuichi Matsuda2,3, Junya Toguchida6,7.
Abstract
Objective: To assess the status of 10 patients with advanced osteonecrosis of the femoral head who underwent mesenchymal stromal cell transplants and a 12-week rehabilitation program 10 years earlier. Design: Retrospective study. Setting: University clinical research laboratory. Participants: Patients (N=10) who had undergone mesenchymal stromal cell transplantation and rehabilitation for a single hip osteonecrosis of the femoral head 10 years prior to the current study were recruited by telephone. The average age was 31.7 years and all participants were men; radiographic stages were 3A in 6 patients and 3B in 4 patients before treatment. Intervention: A 12-week rehabilitation program with follow-up once every 1 to 2 years was performed after mesenchymal stromal cell transplantation. Main Outcome Measures: Radiographic analysis, clinical score, timed Up and Go test, hip function (range of motion, muscle strength), and Short Form-36 scores were assessed before treatment and 1 and 10 years after treatment.Entities:
Keywords: Femur head; Mesenchymal stem cells; Osteonecrosis; Regenerative medicine; Rehabilitation
Year: 2022 PMID: 35282152 PMCID: PMC8904865 DOI: 10.1016/j.arrct.2022.100179
Source DB: PubMed Journal: Arch Rehabil Res Clin Transl ISSN: 2590-1095
Patient data
| Baseline Data | Bodily Composition | Radiographic Evaluation | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Height, cm | Weight, kg | BMI, kg/m2 | Thigh Circumference, cm | Type | JIC Stage: Tx Side | JIC Stage: Non-Tx Side | ||||||||||||||||||
| Group | Patient No. | Age, years | Sex | TS | History | Brinkman index | SU | Pre-Tx | 1Y | 10Y | Pre-Tx | 1Y | 10Y | Pre-Tx | 1Y | 10Y | Pre-Tx | 1Y | 10Y | Pre-Tx | 1Y | 10Y | ||
| Stable group | 2 | 23 | M | L | Cushing syndrome | 0 | Y | 171.0 | 56.6 | 57.6 | 60.2 | 19.4 | 19.7 | 20.6 | 39.0 | 38.5 | 41.0 | C2 | 3A | 3A | 3A | 2 | 2 | 2 |
| 4 | 20 | M | R | Hepatitis | 0 | Y | 174.2 | 76.8 | 72.9 | 70.6 | 25.3 | 24.0 | 23.3 | 50.5 | 50.0 | 53.5 | C1 | 3A | 3A | 3A | 2 | 2 | 2 | |
| 5 | 35 | M | L | None | 300 | N | 178.8 | 70.0 | 59.2 | 62.0 | 21.9 | 18.5 | 19.4 | 43.2 | 38.5 | 38.0 | C2 | 3A | 3A | 3A | THA | THA | THA | |
| 9 | 33 | M | R | None | 0 | N | 174.2 | 61.0 | 65.7 | 70.0 | 20.1 | 21.7 | 23.1 | 42.5 | 42.5 | 44.0 | C2 | 3A | 3A | 3A | 1 | 1 | 1 | |
| 10 | 38 | M | R | None | 300 | N | 166.7 | 52.9 | 52.5 | 54.4 | 19.0 | 18.9 | 19.6 | 40.0 | 38.7 | 38.5 | C2 | 3A | 3A | 3A | 3A | 3B | THA | |
| Progressed group | 1 | 27 | M | R | Nephritis | 300 | Y | 170.9 | 66.5 | 68.7 | 62.0 | 22.8 | 23.5 | 21.2 | 42.5 | 42.0 | 41.0 | C2 | 3B | 3B | 4 | 2 | 2 | 2 |
| 6 | 28 | M | R | None | 300 | N | 169.2 | 58.3 | 63.9 | 53.4 | 20.4 | 22.3 | 18.7 | 40.0 | 44.2 | 42.5 | C2 | 3A | 3A | 4 | 2 | 2 | 2 | |
| 8 | 26 | M | R | None | 105 | N | 175.1 | 66.4 | 73.4 | 65.0 | 21.7 | 23.9 | 21.2 | 44.0 | 47.2 | 46.5 | C2 | 3B | 3B | 4 | 4 | 4 | 4 | |
| 3 | 48 | M | R | Meningioma | 72 | N | 174.7 | 87.5 | 69.6 | 84.0 | 28.7 | 22.8 | 27.5 | 46.2 | 40.0 | 41.0 | C2 | 3B | 3B | THA | 2 | 2 | 2 | |
| 7 | 39 | M | R | Leukemia | 0 | Y | 183.1 | 85.2 | 85.4 | 80.9 | 25.4 | 25.5 | 24.1 | 50.2 | 49.8 | 47.0 | C2 | 3B | 3B | THA | 2 | 3A | THA | |
Abbreviations: BMI, body mass index; L, left; M, male; N, no; R, right; SU, steroid use; THA, total hip arthroplasty; TS, treatment side; Tx, treatment; Y, yes.
Radiogenic classification Japanese Investigation Committee.
Modified version of the radiographic staging system proposed by the American Research Circulation Osseous Committee.
Fig 1Transition of clinical results. (A) Japanese Orthopaedic Association score for hips. (B) timed Up and Go test (in seconds). The blue line indicates the average of the stable group (n=5); the orange line indicates the average of the progressed group without total hip arthroplasty (n=3). *Significant difference between pretreatment and 1 year after the treatment. †Significant difference between pretreatment and 10 years after treatment. P<.05. Tx, treatment; Y, year.
Fig 2Transition of hip range of motion: (A) hip flexion, (B) hip extension, (C) hip abduction, (D) straight leg riding, and (E) hip outer rotation (in degrees). The blue line indicates the average of the stable group (n=5); the orange line indicates the average of the progressed group without total hip arthroplasty (n=3). *Significant difference between pretreatment and 1 year after treatment. **Significant difference between 1 year and 10 years after treatment. †Significant difference between pretreatment and 10 years after treatment. P<.05. Tx, treatment; Y, year.
Fig 3Transition of hip and knee muscle strength. (A) Hip flexor muscle strength. (B) Hip extensor muscle strength. (C) Hip abductor muscle strength. (D) Knee flexor muscle strength. (E) Knee extensor muscle strength (Nm/kg). The blue line indicates the average of the stable group (n=5); the orange line indicates the average of the progressed group without total hip arthroplasty (n=3). *Significant difference between pretreatment and 1 year after treatment. †Significant difference between pretreatment and 10 years after treatment. P<.05. Tx, treatment; Y, year.
Fig 4Transition of Short Form-36 subgroup scores: (A) physical function, (B) role limitations due to physical functioning, (C) bodily pain, (D) general health, (E) vitality, (F) social function, (G) role limitations due to emotional functioning, and (H) mental health. The blue line indicates the average of the stable group (n=3); the orange line indicates the average of the progressed group without total hip arthroplasty (n=2). Tx, treatment; Y, year.